Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Vietnam To Take Steps To Curb Sharp Increase In Drug Costs

This article was originally published in PharmAsia News

Executive Summary

The stability of Vietnam's drug prices has been shaken by a weaker Vietnamese currency coupled with an increase in the cost of imported drugs, the Drug Administration of Vietnam says. The Vietnam Pharmaceutical Companies Association said foreign drugs are expected to rise by as much as 10 percent because of the weaker dong against the U.S. dollar. The head of the Drugs Control Department of Vietnam said local drug companies invested less in their companies last year because of the decline in the economy, but said the DCD would take steps to discourage price increases by inviting more bids and licensing more makers. (Click here for more

You may also be interested in...



FDA's COVID-19 Naughty List Now Includes Marketers Of Copper Germ Stoppers, ‘24-Hour’ Hand Sanitizer

Warning letters issued by the US FDA on 28 May target two companies using COVID-19 and other disease-prevention claims to market purported germ-killing products, including a rub touted as 24-hour protection and a line of copper rollers and other implements to disinfect hands and personal items.

A ‘Fair’ Price For Rare Disease Cures: Payers, Physicians, Patients Weigh In

Industry-funded survey by Charles River Associates explores diverse perceptions about pricing for high-cost cell  treatments – including curative cell and gene therapy – among various stakeholder groups.

Deal Watch: Chinook To Go Public Via Reverse Merger With Troubled Aduro

Focused on precision medicine for renal disease, Chinook gets Aduro’s Nasdaq listing and starting capital of $200m. During a wave of modest-sized M&A deals, Tetra finds buyer, Tetraphase gets competing bids.

UsernamePublicRestriction

Register

RS009715

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel